Main menu
Edison Group
  • Home
  • Equities

    Equities

    View All Equities

    Equities by Sector

    Good Life Plus

    MCap

    GBP12m

    Last close

    GBP0.02

    ▲ 0.40 (22.86%)

    KEFI Gold and Copper

    MCap

    GBP39m

    Last close

    GBP0.01

    ▲ 0.11 (20.00%)

    OSE Immunotherapeutics

    MCap

    EUR132m

    Last close

    EUR6.14

    ▲ 0.68 (12.45%)

  • Sectors

    Sectors

  • Investment Strategy

    Investment Strategy

    View All

    Latest

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

Cereno Scientific (OMX: CRNO-B)

Last close As at 02/07/2024

SEK4.95

▲ 0.19 (3.99%)

Market capitalisation

SEK1,230m

Based in Sweden, Cereno Scientific is focused on the development of innovative, effective and safe treatments for cardiovascular diseases (CVD) with unmet medical needs. Lead asset CS1, an HDAC inhibitor that acts as an epigenetic modulator, is currently being investigated in a Phase II clinical trial for the treatment of pulmonary arterial hypertension (PAH).

CVD encompasses various conditions implicated in the heart and blood vessels. Despite a growing repertoire of treatments, CVD is the most common cause of death worldwide. While rare, PAH is well-recognised and disease-modifying therapies remain the holy grail in this indication. In a market dominated by vasodilators mainly offering symptomatic relief, CS1 claims disease-modifying potential underpinned by its epigenetic modulation properties.

Latest Insights

View More

Healthcare | Flash note

Cereno Scientific — CS1 Phase II results inbound; first dose of CS014

Healthcare | Update

Cereno Scientific — CS014 (second asset) crosses into the clinic

Healthcare | Update

Cereno Scientific — All eyes on Q3 readout after Q1 update

Healthcare | Flash note

Cereno Scientific — CS014 (thrombosis) progresses towards the clinic
Visit Website

Sector

Healthcare

Equity Analyst

Soo Romanoff

Soo Romanoff

Managing Director - Head of Content, Healthcare

Jyoti Prakash

Jyoti Prakash

Analyst, Healthcare

Arron Aatkar

Associate analyst

Key Management

  • Eva Jagenheim

    CFO

  • Joakim Söderström

    Chairman

  • Sten Sörensen

    CEO

Balance Sheet

Forecast net cash (SEKm)

11.7

Forecast gearing ratio (%)

N/A

Share Price Performance

Price Performance
% 1M 3M 12M
Actual 6.2 (1.6) 691.3
Relative 9.2 (2.2) 568.1
52 week high/low SEK5.3/SEK0.5

Financials

Cereno Scientific is a clinical-stage biotech, developing novel treatments for CVD. Its lead asset, CS1, is an HDAC inhibitor with disease-modifying potential for PAH. Top-line results for the Phase II study leveraging Abbott’s CardioMEMS technology are expected in Q324. Interim updates, including the FDA-approved compassionate use programme, have been encouraging, in our view. Given the unmet need, we estimate blockbuster potential, contingent on successful clinical progress. Preclinical candidates include CS014 for thrombosis prevention without increased risk of bleeding, due to enter the clinic in Q224. CS585 is being developed for CVD (specific indication not yet determined); preclinical work is set to continue throughout FY24. We estimate that Cereno’s gross liquidity of c SEK168m should fund it through Q225. We value the company at SEK2.46bn (SEK8.8/share).

Y/E Dec Revenue (SEKm) EBITDA (SEKm) PBT (SEKm) EPS (öre) P/E (x) P/CF (x)
2022A 57.5 (27.5) (27.6) (20.11) N/A N/A
2023A 49.3 (44.6) (46.4) (19.86) N/A N/A
2024E 79.6 (42.6) (49.4) (17.54) N/A N/A
2025E 87.0 (44.8) (47.0) (16.68) N/A N/A

Research

Update

Healthcare

Cereno Scientific — CS014 (second asset) crosses into the clinic

Update

Healthcare

Cereno Scientific — All eyes on Q3 readout after Q1 update

Healthcare

Flash note

Cereno Scientific — CS1 Phase II results inbound; first dose of CS014

Flash note

Healthcare

Cereno Scientific — CS014 (thrombosis) progresses towards the clinic

edison tv

Healthcare

Cereno Scientific – Executive interview with CSO and CMO

edison tv

Healthcare

Cereno Scientific – executive interview

Initiation

Healthcare

Cereno Scientific — Differentiated approach in CVD with potential

Thematics

thematic

Healthcare

Outlook for 2024: Life sciences – where has the conviction gone?

thematic

Healthcare

Deutsches Eigenkapitalforum (EKF) 2023 healthcare
volition01

thematic

Healthcare

VolitionRx – Decoding the DNA of cancer 

thematic

Healthcare

ASCO 2023 key takeaways
View All

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free